Smoldering multiple myeloma: taking the narrow over the wide path?

2.

Kyle

RA

,

Remstein

ED

,

Therneau

TM

, et al.

Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma

.

N Engl J Med

.

2007

;

356

(

25

):

2582

-

2590

.

3.

Thorsteinsdóttir

S

,

Gíslason

GK

,

Aspelund

T

, et al.

Prevalence of smoldering multiple myeloma based on nationwide screening

.

Nat Med

.

2023

;

29

(

2

):

467

-

472

.

4.

Pérez-Persona

E

,

Vidriales

MB

,

Mateo

G

, et al.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

.

Blood

.

2007

;

110

(

7

):

2586

-

2592

.

5.

Lakshman

A

,

Rajkumar

SV

,

Buadi

FK

, et al.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria

.

Blood Cancer J

.

2018

;

8

(

6

):

59

-

66

.

6.

Hill

E

,

Dew

A

,

Morrison

C

, et al.

Assessment of discordance among smoldering multiple myeloma risk models

.

JAMA Oncol

.

2021

;

7

(

1

):

132

-

134

.

7.

Mateos

M-V

,

Kumar

S

,

Dimopoulos

MA

, et al.

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

.

Blood Cancer J

.

2020

;

10

(

10

):

102

-

110

.

8.

Cowan

A

,

Ferrari

F

,

Freeman

SS

, et al.

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

.

Lancet Haematol

.

2023

;

10

(

3

):

e203

-

e212

.

9.

Dang

M

,

Wang

R

,

Lee

HC

, et al.

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

.

Cancer Cell

.

2023

;

41

(

6

):

1032

-

1047.e4

.

10.

Zavidij

O

,

Haradhvala

NJ

,

Mouhieddine

TH

, et al.

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

.

Nat Cancer

.

2020

;

1

(

5

):

493

-

506

.

11.

Sklavenitis-Pistofidis

R

,

Aranha

MP

,

Redd

RA

, et al.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

.

Cancer Cell

.

2022

;

40

(

11

):

1358

-

1373.e8

.

12.

Bailur

JK

,

McCachren

SS

,

Doxie

DB

, et al.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy

.

JCI Insight

.

2019

;

5

(

11

):

e127807

.

13.

Spisek

R

,

Kukreja

A

,

Chen

LC

, et al.

Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy

.

J Exp Med

.

2007

;

204

(

4

):

831

-

840

.

14.

Mateos

MV

,

Hernández

MT

,

Giraldo

P

, et al.

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

.

N Engl J Med

.

2013

;

369

(

5

):

438

-

447

.

15.

Rajkumar

SV

,

Dimopoulos

MA

,

Palumbo

A

, et al.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

.

Lancet Oncol

.

2014

;

15

(

12

):

e538

-

548

.

16.

Lonial

S

,

Jacobus

S

,

Fonseca

R

, et al.

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma

.

J Clin Oncol

.

2020

;

38

(

11

):

1126

-

1137

.

17.

Mina

R

,

Musto

P

,

Rota-Scalabrini

D

, et al.

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

.

Lancet Oncol

.

2023

;

24

(

1

):

64

-

76

.

18.

Burgos

L

,

Tamariz-Amador

L-E

,

Puig

N

, et al.

Definition and clinical significance of the monoclonal gammopathy of undetermined significance–like phenotype in patients with monoclonal gammopathies

.

J Clin Oncol

.

2023

;

41

(

16

):

3019

-

3031

.

https://doi.org/10.1101/2023.08.30.23294483

19.

Kazandjian

D

,

Diamond

B

,

Papadimitriou

M

, et al.

Genomic profiling to contextualize the results of intervention for high-risk smoldering myeloma

.

medRxiv

.

Preprint posted online 31 August 2023

.

20.

Oben

B

,

Froyen

G

,

Maclachlan

KH

, et al.

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

.

Nat Commun

.

2021

;

12

(

1

):

1861

-

1869

.

21.

Bustoros

M

,

Anand

S

,

Sklavenitis-Pistofidis

R

, et al.

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

.

Nat Commun

.

2022

;

13

(

1

):

3449

-

3455

.

22.

Bustoros

M

,

Sklavenitis-Pistofidis

R

,

Park

J

, et al.

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

.

J Clin Oncol

.

2020

;

38

(

21

):

2380

-

2389

.